NeOnc Technologies delivered top-line Phase 2a data for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, reporting a six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark. The company also reported median overall survival of 26.09 months, with 86.7% alive at six months, and said it plans to request a Type B meeting with the FDA on a registrational pathway. In psychedelics, Definium Therapeutics scored another late-stage win in generalized anxiety disorder, reporting that its LSD-based DT-120 cleared the bar in the first of two Phase 3 trials. The company’s results add to prior Phase 3 success in major depressive disorder, strengthening the case for a potential next wave of psychiatric therapeutics. While both sets of results remain early in their respective development pathways, each event shifts near-term decision-making for investors, regulators, and future trial design.